Literature DB >> 28385608

Comparison of the nine polymorphic membrane proteins of Chlamydia trachomatis for their ability to induce protective immune responses in mice against a C. muridarum challenge.

Sukumar Pal1, Alison Favaroni2, Delia F Tifrea1, Philipp T Hanisch2, Sören E T Luczak2, Johannes H Hegemann2, Luis M de la Maza3.   

Abstract

OBJECTIVES: To test vaccines, formulated with novel antigens, to protect mice against Chlamydia infections.
METHODS: To determine the ability of polymorphic membrane proteins (Pmps) to induce cross-species protective immune responses, recombinant fragments from all nine C. trachomatis serovar E Pmps were used to vaccinate BALB/c mice utilizing CpG-1826 and Montanide ISA 720 as adjuvants. C. muridarum recombinant MOMP and PBS, formulated with the same adjuvants, were used as positive and negative controls, respectively. Mice were challenged intranasally with 104 inclusion-forming units (IFU) of C. muridarum. Animals were weighed daily and at 10days post-challenge, they were euthanized, their lungs harvested, weighed and the number of chlamydial IFU counted.
RESULTS: Following vaccination the nine Pmps elicited immune responses. Based on body weight changes, or number of IFU recovered from lungs, mice vaccinated with Pmp C, G or H were the best protected. For example, over the 10-day period, the negative control group vaccinated with PBS lost significantly more body weight than mice immunized with PmpC or G (P<0.05). C. muridarum MOMP vaccinated mice were better protected against body weight losses than any group immunized with Pmps. Also, the median number of IFU recovered from the lungs of mice vaccinated with PmpC (72×106) or PmpH (61×106) was significantly less than from mice immunized with PBS (620×106; P<0.05). As determined by the number of IFU, all Pmps elicited less protection than C. muridarum MOMP (0.078×106 IFU; P<0.05).
CONCLUSIONS: This is the first time PmpC has been shown to elicit cross-species protection against a respiratory challenge. Additional work with Pmps C, G and H is recommended to determine their ability to protect animal models against genital and ocular challenges.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  C. muridarum; C. trachomatis; PmpC; Polymorphic membrane proteins (Pmps); Vaccine

Mesh:

Substances:

Year:  2017        PMID: 28385608      PMCID: PMC5464790          DOI: 10.1016/j.vaccine.2017.03.070

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  48 in total

Review 1.  Polymorphic proteins of Chlamydia spp.--autotransporters beyond the Proteobacteria.

Authors:  I R Henderson; A C Lam
Journal:  Trends Microbiol       Date:  2001-12       Impact factor: 17.079

Review 2.  Chlamydia vaccine candidates and tools for chlamydial antigen discovery.

Authors:  Daniel D Rockey; Jie Wang; Lei Lei; Guangming Zhong
Journal:  Expert Rev Vaccines       Date:  2009-10       Impact factor: 5.217

3.  Prediction of pelvic inflammatory disease among young, single, sexually active women.

Authors:  Roberta B Ness; Kenneth J Smith; Chung-Chou H Chang; Enrique F Schisterman; Debra C Bass
Journal:  Sex Transm Dis       Date:  2006-03       Impact factor: 2.830

4.  Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine.

Authors:  Delia F Tifrea; Guifeng Sun; Sukumar Pal; Gustavo Zardeneta; Melanie J Cocco; Jean-Luc Popot; Luis M de la Maza
Journal:  Vaccine       Date:  2011-05-06       Impact factor: 3.641

5.  Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen.

Authors:  Deborah D Crane; John H Carlson; Elizabeth R Fischer; Patrik Bavoil; Ru-ching Hsia; Chun Tan; Cho-chou Kuo; Harlan D Caldwell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-30       Impact factor: 11.205

6.  Differential expression of Pmp10 in cell culture infected with Chlamydia pneumoniae CWL029.

Authors:  A S Pedersen; G Christiansen; S Birkelund
Journal:  FEMS Microbiol Lett       Date:  2001-09-25       Impact factor: 2.742

7.  Identification of immunodominant antigens by probing a whole Chlamydia trachomatis open reading frame proteome microarray using sera from immunized mice.

Authors:  Maria I Cruz-Fisher; Chunmei Cheng; Guifeng Sun; Sukumar Pal; Andy Teng; Douglas M Molina; Matthew A Kayala; Adam Vigil; Pierre Baldi; Philip L Felgner; Xiaowu Liang; Luis M de la Maza
Journal:  Infect Immun       Date:  2010-10-18       Impact factor: 3.441

8.  The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection.

Authors:  Robert C Brunham; Babak Pourbohloul; Sunny Mak; Rick White; Michael L Rekart
Journal:  J Infect Dis       Date:  2005-10-10       Impact factor: 5.226

9.  Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of mice.

Authors:  Hong Yu; Karuna P Karunakaran; Xiaozhou Jiang; Robert C Brunham
Journal:  Vaccine       Date:  2014-06-30       Impact factor: 3.641

10.  The role of Chlamydia trachomatis polymorphic membrane proteins in inflammation and sequelae among women with pelvic inflammatory disease.

Authors:  Brandie D Taylor; Toni Darville; Chun Tan; Patrik M Bavoil; Roberta B Ness; Catherine L Haggerty
Journal:  Infect Dis Obstet Gynecol       Date:  2011-10-19
View more
  9 in total

1.  Development of Transposon Mutagenesis for Chlamydia muridarum.

Authors:  Yibing Wang; Scott D LaBrie; Steven J Carrell; Robert J Suchland; Zoe E Dimond; Forrest Kwong; Daniel D Rockey; P Scott Hefty; Kevin Hybiske
Journal:  J Bacteriol       Date:  2019-11-05       Impact factor: 3.490

2.  Induction of protection in mice against a respiratory challenge by a vaccine formulated with exosomes isolated from Chlamydia muridarum infected cells.

Authors:  Sukumar Pal; Yeva Mirzakhanyan; Paul Gershon; Delia F Tifrea; Luis M de la Maza
Journal:  NPJ Vaccines       Date:  2020-09-18       Impact factor: 7.344

3.  Pmp Repertoires Influence the Different Infectious Potential of Avian and Mammalian Chlamydia psittaci Strains.

Authors:  Alison Favaroni; Alexander Trinks; Michael Weber; Johannes H Hegemann; Christiane Schnee
Journal:  Front Microbiol       Date:  2021-03-29       Impact factor: 5.640

4.  Cross-Reactive Effects of Vaccines: Heterologous Immunity between Tetanus and Chlamydia.

Authors:  Marijana Stojanovic; Ivana Lukic; Emilija Marinkovic; Ana Kovacevic; Radmila Miljkovic; Joshua Tobias; Irma Schabussova; Mario Zlatović; Talin Barisani-Asenbauer; Ursula Wiedermann; Aleksandra Inic-Kanada
Journal:  Vaccines (Basel)       Date:  2020-12-01

Review 5.  A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections.

Authors:  Abisola Abisoye-Ogunniyan; Isabella M Carrano; Dina R Weilhammer; Sean F Gilmore; Nicholas O Fischer; Sukumar Pal; Luis M de la Maza; Matthew A Coleman; Amy Rasley
Journal:  Front Pharmacol       Date:  2021-11-24       Impact factor: 5.988

6.  A Novel Intranasal Vaccine With PmpGs + MOMP Induces Robust Protections Both in Respiratory Tract and Genital System Posting Chlamydia psittaci Infection.

Authors:  Qiang Li; Siyu Chen; Zhuanqiang Yan; Huanxin Fang; Zhanxin Wang; Cheng He
Journal:  Front Vet Sci       Date:  2022-04-22

7.  Chlamydia trachomatis vaccines for genital infections: where are we and how far is there to go?

Authors:  Luis M de la Maza; Toni L Darville; Sukumar Pal
Journal:  Expert Rev Vaccines       Date:  2021-04-28       Impact factor: 5.217

8.  Prophylactic Multi-Subunit Vaccine against Chlamydia trachomatis: In Vivo Evaluation in Mice.

Authors:  Christian Lanfermann; Sebastian Wintgens; Thomas Ebensen; Martin Kohn; Robert Laudeley; Kai Schulze; Claudia Rheinheimer; Johannes H Hegemann; Carlos Alberto Guzmán; Andreas Klos
Journal:  Vaccines (Basel)       Date:  2021-06-06

9.  Chlamydia trachomatis Polymorphic Membrane Proteins (Pmps) Form Functional Homomeric and Heteromeric Oligomers.

Authors:  Alison Favaroni; Johannes H Hegemann
Journal:  Front Microbiol       Date:  2021-07-19       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.